曲伏前列素滴眼液对青光眼的疗效及基础泪液分泌量的影响-现代医学

曲伏前列素滴眼液对青光眼的疗效及基础泪液分泌量的影响

单位：东风汽车公司茅箭医院眼科, 湖北十堰 442012

分类号：R775

出版年·卷·期（页码）：2017·36·第五期（651-654）

摘要：

目的：探讨曲伏前列素滴眼液对青光眼的疗效及基础泪液分泌量（schirmerⅠtest，SIt）的影响。方法：选择在我院治疗的原发性开角型青光眼患者101例（142眼），采用曲伏前列素滴眼液治疗，观察治疗效果以及患者视力、散光度、眼压及SIt变化情况。结果：142眼中显效96眼（67.61%），有效36眼（25.35%），无效10眼（7.04%），总有效率为92.96%。与治疗前比较，治疗后患者视力明显提高，散光度明显降低（均P < 0.05），治疗后3个月视力和散光度分别为（0.84±0.19）和（1.15±0.81） D；眼压也明显降低（P < 0.05）；治疗后4周与治疗后8周的眼压比较，差异无统计学意义（P > 0.05）；治疗后SIt明显减少（P < 0.05），其中治疗后3个月SIt最少，为（5.98±1.26） mm·（5 min）^-1。治疗期间不良反应发生率为18.31%，未出现严重不良反应。结论：曲伏前列素滴眼液治疗原发性开角型青光眼有较好的疗效，安全性较高，但会引起患者泪液分泌减少。

Objective: To investigate the efficacy of travoprost eye drops in treatment of glaucoma and its effect on schirmerⅠtest(SIt). Methods: One hundred and onecases (142 eyes) ofprimary openangle glaucoma in our hospital were treated with travoprost eye drops, the therapeutic effect and the changes of visual acuity, astigmatism, intraocular pressure and SIt were observed.Results: Among the 142 eyes, 96 eyes (67.61%) were markedly effective, 36 eyes (25.35%) were effective, 10 eyes (7.04%) were invalid, the total effective rate was 92.96%. After treatment the visual acuity was significantly improved and the astigmatism was significantly lower than before treatment (all P<0.05). The visual acuity and astigmatism degree were (0.84±0.19) and (1.15±0.81)D3 months after treatment; the intraocular pressure difference was not statistically significant between 4 and 8 weekstreatment(P>0.05).After treatment SIt was significantly lower than before treatment(P<0.05),which was least at 3 months after treatment[(5.98±1.26) mm·(5 min)^-¹]. The incidence of adverse reactions was 18.31%, and no serious adverse reactions occurred during the treatment. Conclusion: Travoprost eye drops has a good effect in treatment of primary openangle glaucoma and high safety, but it can cause lacrimal secretion decreased.

参考文献：

[1] 武娜,朱文卿,孙兴怀.前列腺素类降眼压药与角膜厚度的变薄(附1例报道)[J].中国眼耳鼻喉科杂志,2012,12(1):54-55.
[2] 何欢,刘祖国,林志荣,等.普拉洛芬治疗苯扎氯铵诱导小鼠干眼的研究[J].中华眼科杂志,2012,48(1):33-40.
[3] 陈慧云.曲伏前列素滴眼液治疗原发性开角型青光眼的临床效果观察[J].中国医师进修杂志,2014,37(9):50-52.
[4] 王俊如,赵秀丽,马科,等.前列腺素受体基因多态性与曲伏前列腺素降眼压疗效的相关性[J].中国临床药理学杂志,2014,30(3):190-193.
[5] 周晓芳,付汛安.曲伏前列素对已行超声乳化人工晶状体植入术的POAG患者的眼压控制[J].国际眼科杂志,2014,22(8):1444-1446.
[6] 董敬民,张效房,马跃伟,等.曲伏前列素治疗原发性开角型青光眼的临床研究[J].眼科新进展,2012,32(12):1174-1175,1178.
[7] 陈光胜,王冬梅,阳昇,等.拉坦前列素、曲伏前列素及贝美前列素滴眼液治疗原发性开角型青光眼降眼压效果比较[J].中国老年学杂志,2013,33(2):445-446.
[8] 谭业双,周霞,樊玲,等.曲伏前列素滴眼液抗青光眼治疗中对眼表影响的观察[J].国际眼科杂志,2014,14(6):1106-1107.
[9] 张志宏,刘文茹,范肃洁,等.黏弹剂在新生血管性青光眼手术中的应用[J].东南大学学报:医学版,2013,32(2):221-223.
[10] 左国进,刘卫容.曲伏前列素滴眼液治疗原发性开角型青光眼患者的疗效与安全性分析[J].航空航天医学杂志,2015,26(8):934-935.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录